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Abstract:  
Pyranuronic β-Sugar amino acids, β-SAAs, are biocompatible and tuneable building blocks of 
foldamers and chimera-peptides. The scalable and economic total synthesis of two Lego-elements is 
described here. These C-4 epimers, Fmoc-GlcAPU(Me)-OH (7) and Fmoc-GalAPU(Me)-OH (8), 
suitable for solid phase peptide synthesis are prepared via a common oxime intermediate (16). The 
new process accomplished in nine consecutive steps starts from methyl-α-D-glucopyranoside (6) is 
fine-tuned, optimized and ready for large-scale and cost-efficient production. 
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Introduction 
The excellent compendiums of Risseeuw et al[1] emphasizes the significance of natural and 
functionalized sugar amino acids (SAAs) in inter- and intracellular events of living organisms during the 
formation of glycomimetics, peptidomimetics, etc.. Nowadays, SAAs are widely used in the design and 
synthesis of foldamers2 as they have i) versatile nature, ii) tunable properties in terms of ring-size, 
stereochemistry, substituents, conformation, iii) adjustable hydrophilic / hydrophobic character as 
function of the free / protected OH-groups. The oligomers of these building blocks are biocompatible 
and biodegradable though could resist against proteolytic enzymes. Homo- and hetero-oligomers 
made from solid phase peptide synthesis (SPPS), comprising the above building blocks could form 
different secondary structural elements and designed backbone scaffolds similarly to those occurring in 
polypeptides and proteins, but of different dynamic properties. [3-7]  
 
Results and Discussion 
Among the large numbers of cyclic SAAs composed of α- to ε-amino acid residues, mainly those of 
furanoid or pyranoid rings were described. The number of furanoid SAAs so far termed is way over 200, 
most of different kinds,[1] while those forming pyranoid ring are significantly fewer, perhaps <100. This 
difference is even more significant when comparing β-SAAs: while more than 6 dozens of furanoid β-
SAAs are known,[1] the related pyranoid derivatives are about 10. These ones are either similar to 2-
amino-2-deoxy-glucopyranosyl carboxylic acids or to 4-amino-4-deoxy-D-glucopyranuronic acids.[1] 
Thus, mostly the uronic acid derivatives of the furanoid ring containing α-, β- or -SAAs were 
synthesized. As building blocks unavailable, the corresponding pyranoid SAAs are seldom used to 
make foldamers, focusing on the easily available D-glucosamine carboxylic acids.[4,8] 
 
 
Figure 1. Molecular structure of our target SAAs (1, 2, unprotected OHs) with their precursors (3, 
4)[15,16í and their carbocyclic analogues (ACHC) 
 
Concerning peptidomimetics and glycomimetics derived from α-AAs, acyclic or cyclic β-AAs (e.g. 
ACPC[9,10] and ACHC[11,12]) and β-SAAs, we have completed the synthesis of selected 3-amino-3-
deoxy-pentofuranuronic acids[13] and studied their coupling potential to form peptido-saccharides.[14] In 
a comparative context, our interest turned towards the hydrophilic version of the well-known foldamer 
building blocks (ACHC) as shown in Figure 1, namely the methyl 4-amino-4-deoxy-α-D-
glucopyranuronic (H-GlcAPU(Me)-OH, 1) and methyl 4-amino-4-deoxy-α-D-galactopyranuronic acids 
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(H-GalAPU(Me)-OH, 2). Their derivatives (3 and 4) though partly described[15-17] earlier, however, they 
never were considered as building blocks for foldamers.  
The synthesis of these two β-SAAs of opposite C-4-configuration was described via two very different 
synthetic pathways: the D-gluco epimer[15] (3) from methyl-α-D-galactopyranoside (5), while the D-
galacto epimer[16] (4) from methyl-α-D-glucopyranoside (6). The reason of the two fully detached 
pathways is that, in both cases the amino function was introduced with the usual sulfonate→azide 
nucleophilic substitution method. Carboxylic functions of both products were formed with the oxidation 
of the terminal -CH2OH groups. The first route involves nine, the second one as many as thirteen 
consecutive steps with overall yields of 39% and 5%, respectively. In addition, both protocols are rather 
costly by using pricy reagents and materials (e.g. methyl-α-D-galactopyranoside, Tf2O, NaCNBH3). 
Additionally, column chromatography was needed to purify each of the intermediates of several 
synthetic steps, making the overall reaction routes environmentally unfriendly and hard to scale up. All 
these conditions forecast serious drawbacks in multigram production. Moreover, with a free amino 
group and with a protected carboxylic group both molecules (3 and 4) are unsuitable for SPPS. To turn 
them into suitable intermediates, two additional steps are to be implemented to make both of the 
appropriately N-protected SAAs: both Fmoc-GlcAPU(Me)-OH (7) and Fmoc-GalAPU(Me)-OH (8). 
Thus, we have taken a conceptually new and economic approach to make both SAAs (7 and 8) from a 
common precursor. First, the methyl α-D-glucopyranoside (6) was converted into methyl 2,3-di-O-
benzyl-α-D-glucopyranoside (11), the key intermediate, and subsequently transformed into both amino 
derivatives (14 and 17) in two parallel pathways. In the other case, 11 was transformed into the oxime 
key intermediate (16) from which the two amino epimers were made following the same reaction 
protocol. Separation of these two epimers was achieved after transformation to Fmoc N-protected 
derivatives during the next step.  
 
 
Scheme 1. Preparation of the benzylated common intermediate (11). Reagents and conditions: i) 
anisaldehyde dimethyl acetal, CSA, DMF, 60°C, 1h, 98%; ii) BnBr, NaH, DMF, rt, 1h, 89%; iii) 
KHSO4.H2O, MeOH, rt, 1h, 98%. 
 
In the first step from methyl-α-D-glucopyranoside (6) the 4,6-anisilidene derivative (9) was made. Both -
OHs of C-2 and C-3 carbon atoms were protected by benzylation[18] (10), and then the 4,6-
deprotection[19] was completed to produce the suitably protected diol (11) as white crystals in an overall 
yield of 85% (Scheme 1). We have considerably improved the efficiency by recovering 98% of the 
anisaldehyde dimethyl acetal. This modification resulted in a gainful recycling of the valuable reagent 
and in addition omitting column chromatography[19] saving both time and a lot of organic solvent.  
To form the amino group, we have selected two possible precursors as shown in Scheme 2. For route 
A, to get the D-galacto epimer (14) an oxazine ring (13) was introduced.[20] In a one-pot reaction diol 11 
was converted to the 6,4-(trichloro-oxazine) derivative (13). After chromatography, the ring was opened 
with 80% aqueous AcOH to give 14 in a good yield. On the other hand, to produce the D-gluco epimer 
(17) (route B) a new oxime (16) intermediate was synthesized. For that the required keto compound 
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(15b) was formed via a stannylene derivative[21] (15a) afterward it was converted to the oxime. Crude 
16 was crystallized from ether-hexane, resulting in a key intermediate, reduced under N2 atmosphere 
with LiAlH4 providing 17 in 57% yield. 
 
 
Scheme 2. New amino group introductions into C-4: A) selective oxazine ring opening to D-galacto 
epimer (14); B) selective oxime reduction to D-gluco epimer (17). Reagents and conditions: i) Cl3CCN, 
DBU, DCM, 0°C, 5 min; ii) Tf2O, Py, 0°C, 5 min; iii) DIPEA, rt, 3.5 h, overall yield 69%; iv) 80% AcOH, 
rt, 30 min, 80%; v) Bu2SnO, toluene, reflux, 12 h; vi) 1,3-dibromo-5,5-dimethylhydantoin (DBDMH), 
CHCl3, rt, 15 min; vii) NH2OH.HCl, NaOAc.3H2O, AcOH, 60°C, 5 h, overall yield 62%; viii) LAH, Et2O, rt, 
24 h, 57%. 
 
Generally, selective reduction methods are applied in modern chemistry due to better yields and simple 
purification methods.[22, 23] However, in some cases non selective approaches are more economical, 
especially, if both epimers are needed. Route B via the oxime intermediate (16) opened a new and 
reasonable synthetic option, namely, to perform a non-selective oxime reduction furnishing both 14 and 
17, eventually, in different ratio. Several reduction protocols were attempted (Table 1 in Supporting 
Information), however, successful reaction was achieved only in acidic medium. This was supported by 
the failure of the reduction with NaBH(OAc)3 in iPrOH. However, using NaBH4 in glacial acetic acid in 
situ forming NaBH(OAc)3 reduced the oxime to 4-deoxy-4-hydroxylamine epimers (18+19). 
Successively, the mixture of 18 and 19 was reduced in an H-Cube reactor with RaNi catalyst in 
methanol (Scheme 3). This new method resulted in both 4-amino-4-deoxy epimers (14+17) in a 1:1 
ratio confirmed by 1H-NMR spectra. Products were isolated in an excellent overall yield of 93%. 
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Scheme 3. The new non-selective reduction of the key oxime intermediate (16) in two steps. Reagents 
and conditions: i) AcOH, NaBH4, rt, 1 h, 98%; ii) H-cube: 80°C, 50 bar, RaNi catalyst, 97%. 
 
To explain the different stereoselectivity of the oxime reductions with LiAlH4 in Et2O or with NaBH4 in 
AcOH, we are proposing here two mechanisms (Figure 2). In the case of LiAlH4 (a), oxime 16 can form 
a four-centered C=N+…Al--H complex in which the bulky [AlH4]- ion can be attached only upper side to 
the pyranoid ring. The result is the stereoselective formation of the D-gluco epimer (17). The crystal 
structure of Z-oxime determined by X-ray diffraction method shows the pyranoid ring conformation and 
that the bulky substituents cause steric crowding only on the upper side of the plane of the oxime 
group, supporting the proposed mechanism for stereoselectivity (Figure 2a and Supporting 
Information). 
 
 
Figure 2. Proposed mechanism of the oxime (16) reduction with (a) LiAlH4 in Et2O and (b) with NaBH4 
in AcOH. 
 
On the other hand, in acidic media the non-selective reduction is caused by the fast protonation of the 
oxime (HN+-OH) resulting in a „carbocation”, which can be attacked by the H- anion from both sides of 
the molecule giving the hydroxylamine epimers (18+19) in a 1:1 ratio (Figure 2b). This “carbocation” 
might be stabilized by a -C=N-OH..O- interaction between the oxime OH and the primary OH-6. The 
existence of this in solution was unambiguously corroborated for both isomers by 1H-1H NOESY 
spectrum of the oxime (16). This exhibits a strong cross peak between N-OH (9.13 ppm) and OH-6 
(2.72 ppm) of the E-oxime (Figure 3). The 1H NMR spectrum also reveals both E- and Z-oximes in 
solution in a 93:7 ratio. 
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Figure 3. a) 1H-1H NOESY spectrum of oxime (16) shows NOESY cross peaks between the oxime 
OHs and the primary OH-6s; b) 3D crystal structure of the Z-oxime shows the intermolecular H-bond 
network. 
 
We notice here that crystal structure of 16 shows a definite intermolecular O-H..O-H bridge between 
the oxime OH and the primary OH-6 of another vicinal oxime molecule shown by cyan colored lines 
(Figure 3b). This arrangement appearing in solution might ease the external protonation of the –N=O 
moiety in 16 forming the „carbocation” in the case of the Z-oxime, too.  
To conclude, the amino group of both D-gluco (14) and D-galacto (17) epimers was N-protected with 
Fmoc group, the primary choice when using SPPS. At this step the two C-4 epimers were separated 
due to their very different solubility in Et2O. Trituration of the mixture yields the D-gluco epimer (20) as 
a white crystal, while the mother liquor treated with hexane results in the D-galacto epimer (21) as 
white oil. The carboxylic function was introduced by using TEMPO-NaOCl oxidation[24] of the CH2OH 
group. Both carboxyl products were obtained in an excellent yield: 97% for the D-gluco (7) and 85% for 
the D-galacto epimer (8), respectively (Scheme 4). 
 
 
Scheme 4. Separation of the two epimers and final oxidation resulting both target β-SAAs (7, 8). i) 
FmocOSu, THF, MeOH: water 2:1, NaHCO3, rt, 24 h, 96% of 20, 75% of 21; ii) TEMPO-NaOCl, KBr, 
DCM, 0°C, 2 h, 96% of 7 and 85% of 8. 
 
These β-SAAs (7, 8) are now appropriate for coupling with SPPS, as i) they are now available in 
multigram-scale; ii) products are soluble and stable in aprotic solvents; iii) their amino groups are 
Fmoc-protected while the OH-groups still benzylated, iv) with a C-terminus -COOH easy to activate. 
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The active ester formation of both diastereoisomers with different coupling reagents were tested and 
found to be stable enough during even longer coupling times (e.g. 24 hours). 
Conclusions 
In conclusion, economic and reasonable pathways were developed to synthesize two new β-sugar 
amino acids, namely, Fmoc-GlcAPU(Me)-OH (7) and Fmoc-GalAPU(Me)-OH (8). The new protocol 
uses only a single starting compound (6) and gives both targeted β-SAAs in good yields. By 
introducing the common key intermediate 16 we opened a new synthetic route to synthesize both of 
the C-4 epimers (14 and 17): the protected 4-amino-4-deoxy-D-gluco- and D-galactopyranoside. The 
non-selective reduction of the new oxime (16) gives a mixture of both C-4 epimers in two steps. 
Separation of them was easily performed afterwards. Additional benefits of this new protocol are as 
follows: i) the column chromatography was omitted at all steps; ii) the valuable anisaldehyde dimethyl 
acetal reagent was almost totally recycled (98%). The scalable synthetic process resulted in Fmoc-
GlcAPU(Me)-OH (7) and Fmoc-GalAPU(Me)-OH (8) in an overall yield of 46% and 32%, respectively. 
These β-SAAs are ready to be used as Lego-elements for SPPS, to make succesfully both homo- and 
heterofoldamers.  
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Experimental Section 
General information, 1H and 13C NMR spectra, Tables and X-ray data for 16 can be found in 
Supporting Information, in the online version. 
Methyl 4,6-O-(4’-methoxybenzylidine)-α-D-glucopyranoside (9) 
In a round-bottom flask methyl α-D-glucopyranoside (6, 40 g, 0.2 mol), camphor sulphonic acid (0.46 g, 
2 mmol) and anisaldehyde dimethyl acetal (41.3 ml, 0.22 mol) was mixed with dry DMF (160 ml). The 
mixture was heated under vacuum at 60 °C to remove the methanol. After 1 hour the temperature was 
raised to 65 °C and the solvent was evaporated. The residual yellowish oil was poured into the mixture 
of ice (100 g), saturated aqueous NaHCO3 (200 ml) and ether (200 ml). The product was filtered then 
washed with petrolether and water to give a white solid (61.3 g, 95%). Rf= 0.67 (EtOAc/methanol 9:1); 
mp. 194°C, mplit
25. 194 °C.  
 
Methyl 2,3-di-O-benzyl-4,6-O-(4’-methoxybenzylidine)-α-D-glucopyranoside (10) 
In a three-necked flask equipped with mechanical stirrer compound 9 (15 g, 0.048 mol) was dissolved 
in dry DMF (200 ml) under Argon at 0°C. Then NaH in 60% mineral oil (4.8 g, 0.12 mol) was added and 
stirred at room temperature for 15 minutes, afterward BnBr (14 ml, 0.12 mol) was added drop wise into 
this mixture and stirred for 1 hour. Then methanol (40 ml) was added and stirred for 30 minutes to stop 
the reaction. The mixture was pour into ice (500 g) and filtered. The residue white solid was crystallized 
from hot ethanol (400 ml) to give white crystals of 10 (21.1 g, 89%). Rf= 0.65 (EtOAc/toluol 1:3); mp. 
142 °C, mplit
25. 143-144 °C. 
 
Methyl 2,3-di-O-benzyl-α-D-glucopyranoside (11) 
The synthesis of 11 was carried out from 10 (26.3 g, 0.053 mol) as described19 with differences in the 
purification, i.e. instead of column chromatography trituration of the crude product with petrolether gave 
the product as white powder (21.2 g, 98%). Rf= 0.18 (EtOAc/petrolether 1:1); mp. 73-75 °C, mplit
26. 73-
75 °C. For recycling the reagent the petrolether phase was concentrated resulting in the anisaldehyde 
dimethyl acetal in excellent yield (9.7 ml, 98%). 
 
Methyl 2,3-di-O-benzyl-α-D-xylopyranoside-4-ulose (15b) 
In a flask equipped with a Dean-Stark apparatus compound 11 (10 g, 0.026 mol) was dissolved in 
toluene (220 ml) and Bu2SnO (7.9 g, 0.032 mol) was added and the mixture was refluxed for 11 hours,  
concentrated subsequently and dried in vacuo for 30 minutes. The residue was dissolved in chloroform 
(220 ml) and DBDMH (4.2 g, 0.014 mol) was added in one portion and stirred until the mixture was 
discolored. It was filtered into 10% Na2S2O3 (150 ml) solution, the aqueous phase was separated and 
extracted with chloroform (100 ml). The combined organic phase was washed twice with water (100 
ml) and dried (sicc. MgSO4). After filtration and concentration yellow oil was obtained (9.5 g). Rf= 0.41 
(EtOAc/petrolether 1:1); IR ν = 3462 (OH), 2956-2869 (CH), 1731 (C=O). The crude product was 
directly converted to oxime (16) without any purification.  
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Methyl 2,3-di-O-benzyl-α-D-xylopyranoside-4-ulose oxime (16) 
At first, NaOAc (10.9 g, 0.08 mol) and hydroxylamine hydrochloride (5.5 g, 0.08 mol) was dissolved in 
acetic acid (100 ml). The mixture was heated to 55 °C and compound 15b (9.9 g, 0.026 mol) in acetic 
acid (50 ml) was added. The solution was stirred under N2 for 6 hours at 55°C. The mixture was poured 
into ice (300 g) and neutralized with saturated aqueous Na2CO3 solution, and then it was extracted with 
hexane twice (2x50 ml), then three times with EtOAc (3x100 ml). The hexane extract was discarded 
and the combined EtOAc phases were washed with saturated aqueous Na2CO3 and water (100 ml). 
The organic phase was dried (sicc. MgSO4), filtered and concentrated in vacuo. The residue was 
solved in ether (50 ml) and crystallized from hexane to give white crystals (6.4 g, 62%). Rf= 0.52 
(EtOAc/petrolether 1:1); mp. 91°C; [α]D22=+101.3, (c=1, chloroform); 
1H NMR (CDCl3)  9.13 (s, 1H, 
OH-oxime), 7.24-7.15 (m, BnO Ar-H), 4.96 (dd,3JH,H= 5.3 and 1.8 Hz, 1H, H-5), 4.76 (d, 3JH,H= 3.7 Hz, 
1H, H-1), 4.53 (d, 3JH,H=11.6 Hz, 1H, BnO-3: CH2A), 4.51 (d, 3JH,H=12.1 Hz, 1H, BnO-2: CH2A), 4.45 (d, 
3JH,H=12.1 Hz, 1H, BnO-2: CH2B), 4.28 (d, 3JH,H=11.6 Hz, 1H, BnO-3: CH2B), 4.06 (d, 3JH,H= 3.4 Hz, 1H, 
H-3), 3.86 (dt, 3JH,H= 11.5 and 5.0 Hz, 1H, H-6A), 3.78-3.74 (overlapped m, 1H, H-6B), 3.77 (overlapped 
t, 3JH,H= 3.6 Hz, 1H, H-2), 3.36 (s, 3H, CH3), 2.72 (very br t, 1H, OH-6); 
13C NMR (CDCl3)  153.0 (C-4), 
137.6 (BnO-3: C-1’), 137.1 (BnO-2: C-1’), 128.6, 128.5, 128.4 (BnO-3: C-2’, C-3’, C-4’, C-5’, C-6’), 
128.2, 128.1, 128.0 (BnO-2: C-2’, C-3’, C-4’, C-5’, C-6’), 97.2 (C-1), 79.0 (C-2), 76.6 (C-3), 72.1 (BnO-
2: CH2’), 70.6 (BnO-3: CH2’), 68.5 (C-5), 62.1 (C-6), 56.6 (CH3). HRMS m/z calculated for C21H26NO6 
[M+H+] 388.1760, found: 388.1761. 
 
Methyl 2,3-di-O-benzyl-4-deoxy-4-hydroxylamino-α-D-glucopyranoside (18) and methyl 2,3-di-O-
benzyl-4-deoxy-4-hydroxylamino-α-D-galactopyranoside (19) 
At first, NaBH4 (2.93 g, 0.077 mol) was added in small portions to glacial acid (50 ml) at 15-20 °C. The 
mixture was stirred for 30 min then 16 (5 g, 0.013 mol) was added in one portion and stirred at room 
temperature for 2 hours. The reaction was treated with water (10 ml) and neutralized with saturated 
aqueous Na2CO3. The mixture was extracted with dichloromethane twice (2x100 ml) and the combined 
organic phases were washed with saturated aqueous Na2CO3 (100 ml), dried (sicc. MgSO4), filtered 
and concentrated in vacuo to give a colorless oil (4.9 g, 98%). Rf=0.41 and 0.46 (EtOAc/petrolether 
1:1). The mixture of 18 and 19 was subsequently converted to the appropriate amine derivatives 
without prior separation. 
 
Methyl 2,3-di-O-benzyl-4-amino-4-deoxy-α-D-glucopyranoside (17) and methyl 2,3-di-O-benzyl-4-
amino-4-deoxy-α-D-galactopyranoside (14) via oxime non-selective reduction 
The mixture of 18 and 19 (4.8 g, 0.012 mol) was dissolved in methanol (620 ml) and was reduced in an 
H-cube reactor: flow velocity set with an HPLC pump to 0.3 ml/min. The hydrogen pressure was set to 
50 bar, the temperature to 80 °C and a cartridge containing RaNi was utilized. Products were 
concentrated in vacuo to give a colorless oil (4.35 g, 97%). The mixture of 14 and 179 was 
subsequently converted to the appropriate Fmoc derivatives without prior separation.  
Compound 17: Rf= 0.31 (EtOAc/methanol 9:1); 
1H NMR (CDCl3)  7.28-7.16 (m, BnO Ar-H), 4.65 
(overlapped d, 3JH,H=11.5 Hz, 1H, BnO-3: CH2A), 4.57 (overlapped d, 3JH,H= 11.5 Hz, 1H, BnO-3: CH2B), 
4.57 (overlapped m, 1H, BnO-2: CH2A), 4.55 (overlapped m, 1H, BnO-2: CH2B), 4.52 (d, 3JH,H=3.6 Hz, 
1H, H-1), 3.63 (overlapped dd, 3JH,H= 6.3 Hz, 2H, H-6A and H-6B), 3.47 (t, 3JH,H= 9.5 Hz, 1H, H-3), 3.41 
(dd, 3JH,H= 9.7 and 3.3 Hz, 1H, H-2), 3.36 (overlapped dd, 3JH,H= 5.1 Hz, 1H, H-5), 3.27 (s, 3H, CH3), 
10 
 
2.60 (t, 1H, 3JH,H= 9.5 Hz, 1H, H-4) 2.29 (very br, 1H, OH-6); 
13C NMR (CDCl3)  138.1, 137.8, (BnO-2: 
C-1’and BnO-3: C-1’), 128.03, 127.9, 127.3 (BnO-3: C-2’, C-3’, C-4’, C-5’, C-6’), 127.45, 127.41, 126.4 
(BnO-2: C-2’, C-3’, C-4’, C-5’, C-6’), 97.7 (C-1), 81.4(C-3), 80.0 (C-2), 72.5 (BnO-2: CH2’), 72.0 (BnO-3: 
CH2’), 70.4 (C-5), 62.9 (C-6), 54.8 (CH3), 54.6 (C-4).  
Compound 14: Rf= 0.22 (EtOAc/methanol 9:1); 
1H NMR (CDCl3)  7.28-7.16 (m, BnO-2 Ar-H, BnO-3 
Ar-H), 4.95 (d, 3JH,H= 11.4 Hz, 1H, BnO-3: CH2A), 4.71(overlapped d, 3JH,H= 12.1 Hz, 1H, BnO-2: CH2A), 
4.64 (overlapped m, 1H, BnO-2: CH2B), 4.57 (overlapped d, 3JH,H= 11.4 Hz, 1H, BnO-3: CH2B), 4.57 
(overlapped, 1H, H-1), 3.73 (overlapped t, 3JH,H= 5.6 Hz, 1H, H-5), 3.72 (overlapped t, 3JH,H= 5.2 Hz, 1H, 
H-6A), 3.72 (overlapped t, 3JH,H= 9.8 Hz, 1H, H-3), 3.69 (overlapped t, 3JH,H= 5.2 Hz, 1H, H-6B), 3.6 (dd, 
3JH,H= 6.4 and 3.7 Hz, 1H, H-2), 3.27 (s, 3H, CH3), 3.21 (dd, 1H, 3JH,H= 3.8 Hz, 1H, H-4) 2.29 (br, 1H, 
OH-6); 13C NMR (CDCl3)  137.9, 137.5, (BnO-2: C-1’and BnO-3: C-1’), 128.1, 128.06, 127.2 (BnO-3: 
C-2’, C-3’, C-4’, C-5’, C-6’), 127.6, 127.5, 126.9 (BnO-2: C-2’, C-3’, C-4’, C-5’, C-6’), 98.11 (C-1), 77.4 
(C-5), 75.1 (BnO-3: CH2’), 75.0 (C-2), 72.8 (BnO-2: CH2’), 68.1, (C-3), 62.4 (C-6), 54.7 (CH3), 51.1 (C-
4).  
 
Methyl N-9-fluorenylmethoxycarbonyl-2,3-di-O-benzyl-4-amino-4-deoxy-α-D-glucopyranoside 
(20) and methyl N-9-fluorenylmethoxycarbonyl-2,3-di-O-benzyl-4-amino-4-deoxy-α-D-
galactopyranoside (21) 
The mixture of compounds 14 and 17 (2.23 g, 6 mmol) were dissolved in a mixture of methanol:water 
2:1 (48 ml) and pH was adjusted to 9 with saturated aqueous NaHCO3, then Fmoc-OSu (2.21 g, 6.53 
mmol) solution in THF (15 ml) was added and stirred for 24 hours, then the THF was evaporated and 
the residue was extracted twice with hexane (2x 50 ml) then three times with EtOAc (3x 50 ml). The 
hexane extract was discarded while the combined EtOAc phases were washed with brine (100 ml), 
dried (sicc. MgSO4), filtered and concentrated in vacuo. The residue was treated with ether to give 
compound 20 as a white solid (1.7 g, 96%), Rf= 0.15 (ether/petrolether 4:1), [α]D22=+28.3 (c=1, 
chloroform); 1H NMR (CDCl3)  7.68 (dd, 3JH,H= 2.4 and 7.2 Hz, 2H, Fmoc-H-6, Fmoc-H-6’), 7.46 (dd, 
3JH,H= 7.0 and 3.0 Hz, 2H, Fmoc-H-3, Fmoc-H-3’), 7.34-7.15 (m, BnO Ar-H, Fmoc-H-4, Fmoc-H-5, 
Fmoc-H-4’, Fmoc-H-5’), 4.81 (d, 3JH,H= 11.7 Hz, 1H, BnO-3: CH2A), 4.70 (d, 3JH,H= 11.2 Hz, 1H, BnO-2: 
CH2A), 4.58 (overlapped, 2H, BnO-2: CH2B, BnO-3: CH2B), 4.53 (d, 3JH,H= 3.3 Hz, 1H, H-1), 4.48 (dd, 
3JH,H= 10.7 and 4.2 Hz, 1H, Fmoc-CH2A), 4.36 (dd, 3JH,H= 10.7 and 4.2 Hz, 1H, Fmoc-CH2b), 4.25 (d, 
3JH,H= 6.9 Hz, 1H, NH), 4.08 (t, 3JH,H= 6.1 Hz, 1H, Fmoc-H-1), 3.58 (overlapped dd, 3JH,H= 9.8 and 3.5 
Hz, 1H, H-4), 3.57 (overlapped t, 3JH,H= 9.5 Hz, 1H, H-3), 3.52 (overlapped dd, 3JH,H= 8.8 and 3.2 Hz, 
1H, H-2), 3.46 (dd, 3JH,H= 12.7 and 7.2 Hz, 1H, H-6A), 3.40 (dd, 3JH,H= 12.7 and 7.2 Hz, 1H, H-6B), 3.25 
(overlapped s, 3H, CH3), 3.25 (overlapped m, 1H, H-5); 
13C NMR (CDCl3)  157.1 (Fmoc-C=O), 143.9, 
143.3 (Fmoc-C-2 and Fmoc-C-2’), 140.9 (Fmoc-C-7 and Fmoc-C-7’), 137.6 (BnO-3: C-1’’), 137.3 
(BnO-2: C-1’), 128.1, 128.0, (Fmoc-C-4 and Fmoc-C-4’ and Fmoc-C-5 and Fmoc-C-5’), 127.9, 127.8, 
127.6, 127.3 (BnO-3: C-2’’, C-3’’, C-4’’, C-5’’ and, BnO-2: C-2’, C-3’, C-4’, C-5’), 127.6 (BnO-3: C-6’’), 
127.5 (BnO-2: C-6’), 124.4 (Fmoc-C-3 and Fmoc-C-3’), 119.6 (Fmoc-C-6 and Fmoc-C-6’), 97.8 (C-1), 
79.6 (C-2), 75.9 (C-3), 74.0 (BnO-3: CH2’’), 72.8 (BnO-2: CH2’), 70.9 (C-5), 66.2 (Fmoc-CH2), 54.8 
(CH3), 51.4 (C-4), 46.8 (Fmoc-C-1). HRMS m/z calculated for C36H38NO7 [M+H+] 596.2648, found: 
596.2631. 
The mother liquor was concentrated and treated with hexane to give compound 21 as a white oil (1.3 g, 
75%). Rf= 0.23 (ether/petrolether 4:1). [α]D22=+44 (c=0.5, chloroform); 
1H NMR (CDCl3)  7.69 (d, 3JH,H= 
7.6 Hz, 2H, Fmoc-H-6, Fmoc-H-6’), 7.50 (t, 3JH,H= 6.4 Hz, 2H, Fmoc-H-4, Fmoc-H-4’), 7.33-7.17 (m, 
14H, BnO-2 Ar-H, BnO-3 Ar-H, Fmoc-H-3, Fmoc-H-5, Fmoc-H-3’, Fmoc-H-5’), 4.92 (d, 3JH,H= 8.5 Hz, 
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1H, NH), 4.77 (d, 3JH,H= 12.8 Hz, 1H, BnO-3: CH2A), 4.63 (overlapped d, 3JH,H= 12.8 Hz, 1H, BnO-3: 
CH2B), 4.62 (overlapped d, 3JH,H= 11.6 Hz, 2H, BnO-2: CH2A), 4.53 (d, 3JH,H= 3.5 Hz, 1H, H-1), 4.50 (d, 
3JH,H= 11.6 Hz, 1H, BnO-2: CH2B), 4.44 (dd, 3JH,H= 10.7 and 6.5 Hz, 1H, Fmoc-CH2A), 4.38 (dd, 3JH,H= 
10.7 and 6.5 Hz, 1H, Fmoc-CH2b), 4.27 (dd, 3JH,H= 8.2 and 4.9 Hz, 1H, H-4), 4.13 (t, 3JH,H= 6.7 Hz, 1H, 
Fmoc-H-1), 3.94 (dd, 3JH,H= 9.9 and 4.4 Hz, 1H, H-5), 3.82 (t, 3JH,H= 6.9 Hz, 1H, H-3), 3.45 (m, 1H, H-
6A), 3.40 (dd, 3JH,H= 9.8 and 3.3 Hz, 1H, H-2), 3.35 (m, 1H, H-6B), 3.28 (s, 3H, CH3), 3.03 (br t, 3JO,H= 
5.4 Hz, 1H, OH-6); 13C NMR (CDCl3)  158.0 (Fmoc-C=O), 143.7, 143.4 (Fmoc-C-2 and Fmoc-C-2’), 
141.3, 141.2 (Fmoc-C-7 and Fmoc-C-7’), 138.1 (BnO-3: C-1’’), 137.8 (BnO-2: C-1’), 128.4, 128.3 
(BnO-3: C-2’’, C-6’’, BnO-2: C-2’, C-6’), 127.9, 127.8 (BnO-3: C-3’’, C-5’’, BnO-2: C-3’, C-5’), 127.71, 
127.70 (BnO-3: C-4’’, BnO-2: C-4’), 127.69, 127.94, 127.04, 127.02 (Fmoc-C-4 and Fmoc-C-4’ and 
Fmoc-C-5 and Fmoc-C-5’), 124.9, 124.8 (Fmoc-C-3 and Fmoc-C-3’), 119.97, 119.95 (Fmoc-C-6 and 
Fmoc-C-6’), 98.3 (C-1), 75.5 (C-3), 75.3 (C-2), 73.5 (BnO-3: CH2’’), 71.4 (BnO-2: CH2’), 68.5 (C-5), 
66.9 (Fmoc-CH2), 60.8 (C-6), 55.4 (CH3), 49.7 (C-4), 47.2 (Fmoc-C-1). HRMS m/z calculated for 
C36H38NO7 [M+H+] 596.2648, found: 596.2645. 
 
Methyl N-9-fluorenylmethoxycarbonyl-2,3-di-O-benzyl-4-amino-4-deoxy-α-D-glucopyranoside 
uronic acid (7) 
Compound 20 (2.36 g, 4 mmol) was dissolved in THF:saturated aqueous NaHCO3 1:1 (96 ml) at 0°C 
and TEMPO (125 mg, 0.8 mmol) and KBr (141 mg, 1.2 mmol) were added; to this mixture 0.47 M 
NaOCl (17.6 ml) was added dropwise at 0°C. After 1 hour an additional amounts of NaOCl (8 ml) and 
TEMPO (60 mg) were added and stirred for another 1 hour at 0°C. The solution was extracted with 
hexane twice (2x 20 ml). The aqueous layer was acidified with saturated aqueous NaHSO4 to pH 3 and 
extracted with EtOAc four times (4x50 ml). The hexane extracts were discarded while the combined 
EtOAc layers were dried (sicc. MgSO4), filtered and concentrated. The residue was treated with 
hexane (30 ml) to give the desired product as white solids (2.35 g, 97%). Rf= 0.18 
(methanol/EtOAc/AcOH 9:1:0.01); mp. 158-160°C; [α]D22 = 35.9, (c=0.48, chloroform); 
1H NMR (DMSO-
d6)  7.88 (d, 3JH,H= 7.5 Hz, 2H, Fmoc-H-6, Fmoc-H-6’), 7.70 (dd, 3JH,H= 7.4 Hz, 2H, Fmoc-H-3, Fmoc-
H-3’), 7.65 (d, 3JH,H= 7.6 Hz, 1H, NH), 7.40-7.18 (m, 14H, BnO Ar-H, Fmoc-H-4, Fmoc-H-5, Fmoc-H-4’, 
Fmoc-H-5’), 4.91 (d, 3JH,H= 3.31 Hz, 1H, H-1), 4.70 (d, 3JH,H= 11.2 Hz, 1H, BnO-3: CH2A), 4.65 
(overlapped d, 3JH,H= 12.04 Hz, 1H, BnO-2: CH2A), 4.64 (d, 3JH,H= 11.8 Hz, 1H, BnO-2: CH2B), 4.55 (d, 
3JH,H= 11.2 Hz, 1H, BnO-3: CH2B), 4.26 (overlapped d, 3JH,H= 9.02 Hz, 1H,), 4.16 (overlapped d, 3JH,H= 
9.02 Hz, 1H, Fmoc-CH2A), 4.14 (overlapped t, 1H, Fmoc-H-1), 4.03 (d, 3JH,H= 10.5 Hz, 1H, H-5), 3.83 (t, 
3JH,H= 9.7 Hz, 1H, H-3), 3.69 (dd, 3JH,H= 10.1 Hz, 1H, H-4), 3.51 (dd, 3JH,H= 9.5 and 3.4 Hz, 1H, H-2), 
3.33 (s, 3H, CH3); 
13C NMR (DMSO-d6)  169.9 (COOH-6), 155.7 (Fmoc-C=O), 143.8, 143.7 (Fmoc-C-
2 and Fmoc-C-2’), 140.6 (Fmoc-C-7 and Fmoc-C-7’), 138.6 (BnO-3: C-1’’), 138.4 (BnO-2: C-1’), 128.2, 
127.9, 127.6, 127.5 (BnO-3: C-2’’, C-3’’, C-4’’, C-5’’, C-6’’ and, BnO-2: C-2’, C-3’, C-4’, C-5’, C-6’), 
127.2 (Fmoc-C-5 and Fmoc-C-5’), 127.0 (Fmoc-C-4 and Fmoc-C-4’), 125.3, 125.1 (Fmoc-C-3 and 
Fmoc-C-3’), 120.1 (Fmoc-C-6 and Fmoc-C-6’), 97.6 (C-1), 79.2 (C-3), 77.9 (C-2), 74.3 (BnO-3: CH2’), 
71.4 (BnO-2: CH2’’), 69.9 (C-5), 65.7 (Fmoc-CH2), 55.0 (CH3), 54.0 (C-4), 46.5 (Fmoc-C-1). HRMS m/z 
calculated for C36H36NO8 [M+H+] 610.2441, found: 610.2450. 
 
Methyl N-9-fluorenylmethoxycarbonyl-2,3-di-O-benzyl-4-amino-4-deoxy-α-D-galactopyranoside 
uronic acid (8) 
Compound 8 was synthesized as described for 7 from 21 (1.20 g, 2 mmol): 8 was isolated as a white 
powder (1.04 g, 85%). Rf= 0.38 (methanol/EtOAc/AcOH 9:1:0.01); mp. 75-78 °C; [α]D22= +58.4, (c=0.49, 
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chloroform); 1H NMR (DMSO-d6)  7.89 (d, 3JH,H= 7.5 Hz, 2H, Fmoc-H-6,Fmoc-H-6’), 7.77 (dd, 3JH,H= 
7.4 Hz, 2H, Fmoc-H-3, Fmoc-H-3’), 7.64 (d, 3JH,H= 10.6 Hz, 1H, NH), 7.44-7.18 (m, 14H, BnO Ar-H, 
Fmoc-H-4, Fmoc-H-5, Fmoc-H-4’, Fmoc-H-5’), 4.86 (d, 3JH,H= 5.31 Hz, 1H, H-1), 4.72 (overlapped d, 
3JH,H= 11.7 Hz, 1H, BnO-3: CH2A), 4.71 (overlapped t, 1H, H-4), 4.69 (overlapped d, 3JH,H= 11.8 Hz, 1H, 
BnO-2: CH2A), 4.59 (d, 3JH,H= 11.8 Hz, 1H, BnO-2: CH2B), 4.49 (d, 3JH,H= 11.7 Hz, 1H, BnO-3: CH2B), 
4.38 (d, 3JH,H= 1.7 Hz, 1H, H-5), 4.18 (overlapped t, 1H, Fmoc-H-1), 4.17 (overlapped m, 2H, Fmoc-
CH2), 4.0 (dd, 3JH,H= 10.4 and 6.7 Hz, 1H, H-3), 3.92 (dd, 3JH,H= 10.2 and 5.9 Hz, 1H, H-2), 3.30 (s, 3H, 
CH3); 
13C NMR (DMSO-d6)  169.1 (COOH-6), 156.2 (Fmoc-C=O), 143.8, 143.7 (Fmoc-C-2 and Fmoc-
C-2’), 140.6 (Fmoc-C-7 and Fmoc-C-7’), 138.9 (BnO-3: C-1’’), 138.6 (BnO-2: C-1’), 128.0, 127.9, 127.6, 
127.3 (BnO-3: C-2’’, C-3’’, C-4’’, C-5’’, C-6’’ and, BnO-2: C-2’, C-3’, C-4’, C-5’, C-6’), 127.3 (Fmoc-C-5 
and Fmoc-C-5’), 127.2 (Fmoc-C-4 and Fmoc-C-4’), 125.5 (Fmoc-C-3 and Fmoc-C-3’), 120.0 (Fmoc-C-
6 and Fmoc-C-6’), 98.2 (C-1), 75.4 (C-2), 74.8 (C-3), 71.8 (BnO-2: CH2’), 70.2 (BnO-3: CH2’’), 68.3 (C-
5), 65.8 (Fmoc-CH2), 50.5 (C-4), 46.5 (Fmoc-C-1). HRMS m/z calculated for C36H36NO8 [M+H+] 
610.2441, found: 610.2440. 
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